Joint Formulary & PAD

Canagliflozin - Diabetes Mellitus

You are here : Home > Formulary Search > Canagliflozin - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

Dapagliflozin is the preferred SGLT-2.

Canagliflozin is not a preferred treatment option. Canagliflozin (Invokana?, Vokanamet?): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients - GOV.UK.

Trusts restrict to diabetic team initiation only.

Documentation

NICE Technology Appraisal
NICE TA390 - SGLT-2s for treating Type 2 diabetes - May 2016
NICE Technology Appraisal
NICE TA315 - Canagliflozin in combination therapy for treating Type 2 Diabetes
Patient resource
Getting the most from your SGLT2 inhibitor (gliflozin) medicine - Patient information - Feb 25
Miscellaneous
SGLT2 inhibitors - Prescribing Initiation checklist - Aug 2015
Information
Blood glucose control - Treatment algorithm - June 2022.pdf
Information
Antidiabetic treatments comparison- PrescQIPP resource - February 2018

PAD Profile

ChemicalSubstance :
Canagliflozin
Indication :
Diabetes Mellitus
Group Name :
SGLT2s
Keywords :
SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA
Brand Names Include :
Invokana, Vokanamet
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Diabetes Mellitus
Supporting Documents :
6

Committee Recommendations (3)

03 Sep 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that dapagliflozin will be the preferred SGLT-2 inhibitor in type 2 diabetes, Chronic Kidney Disease and Heart Failure

10 Feb 25 - Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

07 Feb 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Not a preferred treatment option.

See guidelines below and associated documentation for further information

PCN noted that Canagliflozin is a treatment option in NICE TA 315 & TA390

Other Indications

Below are listed other indications that Canagliflozin is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.